Cancer drug nilotinib tested for lewy body dementia in small trial
NCT ID NCT04002674
First seen Apr 04, 2026 · Last updated May 13, 2026 · Updated 4 times
Summary
This study tested the drug nilotinib, already approved for leukemia, in 43 people with Dementia with Lewy Bodies (DLB). The main goal was to see if the drug is safe and tolerable in this group. Researchers also measured changes in brain proteins and amyloid plaques using spinal fluid and PET scans. The trial was completed and double-blind, meaning neither patients nor doctors knew who got the real drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.